A new study is shedding further light on the link between aging and neurodegenerative disease, after researchers found that protein turnover occurs about 20% slower in the brains of older mice compared with younger mice, affecting distinct pathways linked to these diseases.
New research points a finger at a previously unknown long noncoding RNA (lncRNA) as playing a critical role in activating nuclear factor kappa B (NF-kappaB) inflammatory responses and driving the progression of osteoarthritis of the knee.
Jack Taunton and colleagues from the University of California, San Francisco have developed salicylaldehyde-based chemical probes that reversibly and covalently modify the catalytic lysine of protein kinases, with sustained occupancy in cells and animals.
Variable expression of an enzyme in the initial tumor has been identified as an early step in the process of migration and growth of cells to form remote metastases in breast cancer.
A German-Danish team of researchers has developed a new imaging technology that is able to quantify the number of expressed proteins in a given cell, map tissue and cell-type specific proteomes, and identify drug targets.
A multicenter Japanese study led by researchers at Tokyo University of Science has confirmed that the epithelial phospholipid, phosphatidylinositol bisphosphate, could partially halt cancer progression, making it an attractive new target molecule for novel anticancer treatments.
Findings from three recent studies are shedding light on the pathways that are activated in severe cases of COVID-19, paving the way for earlier diagnosis and more targeted treatments.
A target-agnostic search has yielded a patient-derived antibody that activated the innate immune system, researchers from Atreca and Stanford University reported in the May 4,2022, issue of the ProceedingsoftheNationalAcademyofSciences.
Age is the biggest risk factor for just about every common disease in high-income countries, which suggests that slowing down cellular aging would have massive effects on individual and public health. Delaying the average onset of Alzheimer’s disease by five years, for example, would roughly halve its prevalence. But in practice, there are no approved anti-aging medications.
RSS
